Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/bmt.2012.51 http://scihub22266oqcxt.onion/10.1038/bmt.2012.51 C4893814!4893814!22426752     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Bone+Marrow+Transplant 2012 ; 47 (11): 1448-54 Nephropedia Template TP {{tp|p=22426752|t=2012. A Phase I/II Study of Cyclophosphamide and Topotecan in Patients with High-Risk Malignancies Undergoing Autologous Hematopoietic Cell Transplantation: The St Jude Long-term Follow-up |pdf=|usr=}}{{22426752}} gab.com Text A Phase I/II Study of Cyclophosphamide and Topotecan in Patients with High-Risk Malignancies Undergoing Autologous Hematopoietic Cell Transplantation: The St Jude Long-term Follow-up JO: Bone Marrow Transplant http://www.kidney.de/pget.php?&tw=1&pmid=22426752 #FOAvip Fifty-eight consecutive children with high-risk malignancies were treated with cyclophosphamide and targeted topotecan followed by autologous hematopoietic cell transplantation (AHCT) in a phase I/II IRB-approved study. Twelve participants enrolled in phase I; 5 received dose level 1 of topotecan 3mg/m2/day with subsequent doses targeted to total systemic exposure of 100 ± 20 ng°hr/ml and cyclophosphamide 750mg/m2/day. Seven participants received dose level 2. Cyclophosphamide dose escalation to 1g/m2/day was considered excessively toxic; 1 died from irreversible veno-occlusive disease and 2 experienced reversible hepatotoxicity. These adverse events halted further dose escalation. Forty-six participants were enrolled in phase II; results are on the 51 participants who received therapy at dose level 1, the maximum tolerated dose. Diagnoses included neuroblastoma (26), sarcoma (9), lymphoma (8), brain tumors (5), Wilms (2) and retinoblastoma (1). Twenty participants (39.3%) were in ? CR1 at enrollment; median age was 5.1 years. Most common non-hematologic grade 3/4 toxicity was gastrointestinal (n=37). Neutrophil and platelet engraftment occurred at a median of 15 and 24 days, respectively. Twenty-six (51%) remain alive at a median of 6.4 years after AHCT. Cyclophosphamide 3.75g/m2 and targeted topotecan followed by AHCT is feasible and produces acceptable toxicity in children with high-risk malignancies. Twit Text FOAVip A Phase I/II Study of Cyclophosphamide and Topotecan in Patients with High-Risk Malignancies Undergoing Autologous Hematopoietic Cell Transplantation: The St Jude Long-term Follow-up ????Bone Marrow Transplant http://www.kidney.de/pget.php?&tw=1&pmid=22426752 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22426752 #FOAvip English Wikipedia <ref>{{Cite pmid|22426752}}</ref> A Phase I/II Study of Cyclophosphamide and Topotecan in Patients with High-Risk Malignancies Undergoing Autologous Hematopoietic Cell Transplantation: The St Jude Long-term Follow-up #MMPMID22426752 Kasow KA; Stewart CF; Barfield RC; Wright NL; Li C; Srivastava DK; Leung W; Horwitz EM; Bowman LC; Handgretinger R; Hale GA Bone Marrow Transplant 2012[Nov]; 47 (11): 1448-54 PMID22426752show ga Fifty-eight consecutive children with high-risk malignancies were treated with cyclophosphamide and targeted topotecan followed by autologous hematopoietic cell transplantation (AHCT) in a phase I/II IRB-approved study. Twelve participants enrolled in phase I; 5 received dose level 1 of topotecan 3mg/m2/day with subsequent doses targeted to total systemic exposure of 100 ± 20 ng°hr/ml and cyclophosphamide 750mg/m2/day. Seven participants received dose level 2. Cyclophosphamide dose escalation to 1g/m2/day was considered excessively toxic; 1 died from irreversible veno-occlusive disease and 2 experienced reversible hepatotoxicity. These adverse events halted further dose escalation. Forty-six participants were enrolled in phase II; results are on the 51 participants who received therapy at dose level 1, the maximum tolerated dose. Diagnoses included neuroblastoma (26), sarcoma (9), lymphoma (8), brain tumors (5), Wilms (2) and retinoblastoma (1). Twenty participants (39.3%) were in ? CR1 at enrollment; median age was 5.1 years. Most common non-hematologic grade 3/4 toxicity was gastrointestinal (n=37). Neutrophil and platelet engraftment occurred at a median of 15 and 24 days, respectively. Twenty-six (51%) remain alive at a median of 6.4 years after AHCT. Cyclophosphamide 3.75g/m2 and targeted topotecan followed by AHCT is feasible and produces acceptable toxicity in children with high-risk malignancies. äA Phase I/II Study of Cyclophosphamide and Topotecan in Patients with (epmc).pdf DeepDyve Pubget Overpricing